Frontage Laboratories Unveils New GMP Facility for Clinical Trials and Production
Frontage Laboratories, Inc., a prominent player in the contract development and manufacturing organization (CDMO) sector, has recently announced the completion and full operational status of its state-of-the-art GMP facility. The facility, which officially began operations in May 2025, achieved its GMP validation in October 2025, marking a significant step forward in supporting the needs of clinical trials and commercial production.
Located in Exton, Pennsylvania, the new facility has been designed with a focus on drug development and manufacturing capabilities, specifically catering to sterile, non-sterile, oral solid, and liquid dosage forms. This cutting-edge facility features GMP manufacturing rooms classified according to ISO standards, including dedicated containment suites for the handling of high-potency compounds, as well as individual manufacturing suites for a variety of products such as tablets, capsules, ointments, gels, and oral liquids. Additionally, it houses aseptic suites specifically built for producing sterile products including vials, syringes, and cartridges, alongside formulation development rooms, analytical labs, and microbiological testing facilities.
Frontage's substantial investment in this new facility is evident in the addition of advanced equipment designed to streamline the manufacturing process. Key enhancements include three automated aseptic filling machines for vials, syringes, and cartridges, as well as two additional isolators aimed at improving the safety and efficiency of potent compound handling and aseptic filling. The facility also features a new Gerties roller compactor, Korsch tablet press, Xcelodose system, and specialized labelers, among other supportive equipment. These innovations are expected to reduce the time required to bring critical medicines to market, ultimately enhancing the efficiency and quality of Frontage's manufacturing solutions.
Dr. Song Li, Chairman of Frontage, emphasized the significance of this facility in strengthening the company’s role as a comprehensive partner in pharmaceutical development. He stated, "With this fully operational GMP facility featuring newly installed commercial-scale equipment and systems, Frontage helps clients achieve a faster time-to-market by managing every step of the pharmaceutical development and manufacturing process." The company firmly believes that its pharmaceutical solutions will provide customers with optimized cost and quality, thereby supporting improved patient access to medications on a global scale.
Frontage Laboratories operates as a wholly-owned subsidiary of Frontage Holdings Corporation, which is listed on the Hong Kong Stock Exchange (stock code: 1521.HK). With a robust portfolio of services that spans from drug discovery through to late-phase clinical trials and manufacturing, the company brings over 25 years of experience in assisting pharmaceutical and biotechnology firms. Services provided by Frontage include drug discovery, API synthesis, safety and toxicology assessments, formulation development, GMP manufacturing, analytical services, clinical trials, and bioanalytical services, thus positioning itself as a one-stop solution for clients in securing regulatory approvals across various major markets including the U.S., Canada, Europe, and Asia.
For more information about Frontage Laboratories and its services, visit their official website at www.frontagelab.com or reach out via email at [email protected].
Located in Exton, Pennsylvania, the new facility has been designed with a focus on drug development and manufacturing capabilities, specifically catering to sterile, non-sterile, oral solid, and liquid dosage forms. This cutting-edge facility features GMP manufacturing rooms classified according to ISO standards, including dedicated containment suites for the handling of high-potency compounds, as well as individual manufacturing suites for a variety of products such as tablets, capsules, ointments, gels, and oral liquids. Additionally, it houses aseptic suites specifically built for producing sterile products including vials, syringes, and cartridges, alongside formulation development rooms, analytical labs, and microbiological testing facilities.
Frontage's substantial investment in this new facility is evident in the addition of advanced equipment designed to streamline the manufacturing process. Key enhancements include three automated aseptic filling machines for vials, syringes, and cartridges, as well as two additional isolators aimed at improving the safety and efficiency of potent compound handling and aseptic filling. The facility also features a new Gerties roller compactor, Korsch tablet press, Xcelodose system, and specialized labelers, among other supportive equipment. These innovations are expected to reduce the time required to bring critical medicines to market, ultimately enhancing the efficiency and quality of Frontage's manufacturing solutions.
Dr. Song Li, Chairman of Frontage, emphasized the significance of this facility in strengthening the company’s role as a comprehensive partner in pharmaceutical development. He stated, "With this fully operational GMP facility featuring newly installed commercial-scale equipment and systems, Frontage helps clients achieve a faster time-to-market by managing every step of the pharmaceutical development and manufacturing process." The company firmly believes that its pharmaceutical solutions will provide customers with optimized cost and quality, thereby supporting improved patient access to medications on a global scale.
Frontage Laboratories operates as a wholly-owned subsidiary of Frontage Holdings Corporation, which is listed on the Hong Kong Stock Exchange (stock code: 1521.HK). With a robust portfolio of services that spans from drug discovery through to late-phase clinical trials and manufacturing, the company brings over 25 years of experience in assisting pharmaceutical and biotechnology firms. Services provided by Frontage include drug discovery, API synthesis, safety and toxicology assessments, formulation development, GMP manufacturing, analytical services, clinical trials, and bioanalytical services, thus positioning itself as a one-stop solution for clients in securing regulatory approvals across various major markets including the U.S., Canada, Europe, and Asia.
For more information about Frontage Laboratories and its services, visit their official website at www.frontagelab.com or reach out via email at [email protected].
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.